KR20230107589A - 트랜스페린 수용체 1 (TfR1)에 특이적인 비시클릭 펩티드 리간드 - Google Patents

트랜스페린 수용체 1 (TfR1)에 특이적인 비시클릭 펩티드 리간드 Download PDF

Info

Publication number
KR20230107589A
KR20230107589A KR1020237017137A KR20237017137A KR20230107589A KR 20230107589 A KR20230107589 A KR 20230107589A KR 1020237017137 A KR1020237017137 A KR 1020237017137A KR 20237017137 A KR20237017137 A KR 20237017137A KR 20230107589 A KR20230107589 A KR 20230107589A
Authority
KR
South Korea
Prior art keywords
seq
referred
iii
isyc
syndrome
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020237017137A
Other languages
English (en)
Korean (ko)
Inventor
엘렌 고완스
젬마 머드
마이클 릭비
푸닛 세스
마이클 스키너
스티븐 스탠웨이
리우드비카스 얼보나스
리엣슈텐 케이터린 반
Original Assignee
바이사이클티엑스 리미티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB2017927.1A external-priority patent/GB202017927D0/en
Priority claimed from GBGB2106903.4A external-priority patent/GB202106903D0/en
Application filed by 바이사이클티엑스 리미티드 filed Critical 바이사이클티엑스 리미티드
Publication of KR20230107589A publication Critical patent/KR20230107589A/ko
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/107—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
    • C07K1/1072—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups
    • C07K1/1075—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups by covalent attachment of amino acids or peptide residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/64—Cyclic peptides containing only normal peptide links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Analytical Chemistry (AREA)
  • Immunology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
KR1020237017137A 2020-11-13 2021-11-12 트랜스페린 수용체 1 (TfR1)에 특이적인 비시클릭 펩티드 리간드 Pending KR20230107589A (ko)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
GBGB2017927.1A GB202017927D0 (en) 2020-11-13 2020-11-13 Bicyclic peptide ligands specific for transferrin
GB2017927.1 2020-11-13
GB2106903.4 2021-05-14
GBGB2106903.4A GB202106903D0 (en) 2021-05-14 2021-05-14 Bicycle peptide ligands specific for transferrin
US202163261820P 2021-09-29 2021-09-29
US63/261,820 2021-09-29
PCT/GB2021/052927 WO2022101633A1 (en) 2020-11-13 2021-11-12 BICYCLIC PEPTIDE LIGANDS SPECIFIC FOR TRANSFERRIN RECEPTOR 1 (TfR1)

Publications (1)

Publication Number Publication Date
KR20230107589A true KR20230107589A (ko) 2023-07-17

Family

ID=81600834

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020237017137A Pending KR20230107589A (ko) 2020-11-13 2021-11-12 트랜스페린 수용체 1 (TfR1)에 특이적인 비시클릭 펩티드 리간드

Country Status (12)

Country Link
US (3) US11970555B2 (https=)
EP (1) EP4244235A1 (https=)
JP (1) JP7848202B2 (https=)
KR (1) KR20230107589A (https=)
CN (1) CN116802190A (https=)
AR (1) AR126029A1 (https=)
AU (1) AU2021376917A1 (https=)
CA (1) CA3201414A1 (https=)
IL (1) IL302713A (https=)
MX (1) MX2023005624A (https=)
SA (1) SA523440745B1 (https=)
WO (1) WO2022101633A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20230107589A (ko) 2020-11-13 2023-07-17 바이사이클티엑스 리미티드 트랜스페린 수용체 1 (TfR1)에 특이적인 비시클릭 펩티드 리간드
GB202206431D0 (en) * 2022-05-03 2022-06-15 Bicycletx Ltd Bicyclic peptide ligands specific for transferrin receptor 1 (TfR1)
EP4689119A1 (en) * 2023-04-05 2026-02-11 Ionis Pharmaceuticals, Inc. Compounds and methods for reducing pln expression
WO2025073871A1 (en) 2023-10-03 2025-04-10 Bicycletx Limited Bicyclic peptide ligand complexes specific for tfr1
GB202316970D0 (en) * 2023-11-06 2023-12-20 Bicycletx Ltd Bicyclic peptide ligands specific for transferrin receptor 1 (TfR1)

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2653545A1 (en) 2008-02-05 2013-10-23 Bicycle Therapeutics Limited Methods and compositions
GB0914110D0 (en) 2009-08-12 2009-09-16 Medical Res Council Peptide libraries
EP3218411B1 (en) * 2014-11-14 2022-01-12 Ossianix, Inc. Variable new antigen receptors (vnars) directed against transferrin receptor (tfr) and their use
CN104650186A (zh) 2015-03-09 2015-05-27 中国药科大学 一种能够与TfR1特异性结合的活性肽及其应用
GB201706477D0 (en) * 2017-04-24 2017-06-07 Bicycle Therapeutics Ltd Modification of polypeptides
US10857196B2 (en) * 2017-04-27 2020-12-08 Bicycletx Limited Bicyclic peptide ligands and uses thereof
JP7670481B2 (ja) 2017-08-04 2025-04-30 バイスクルテクス・リミテッド Ｃｄ１３７に対して特異的な二環式ペプチドリガンド
WO2019089395A1 (en) 2017-11-02 2019-05-09 Ossianix, Inc. Improved tfr-selective binding peptides capable of crossing the blood brain barrier
CN111902429A (zh) 2018-02-23 2020-11-06 拜斯科技术开发有限公司 多聚体双环肽配体
WO2020084305A1 (en) 2018-10-23 2020-04-30 Bicycletx Limited Bicyclic peptide ligands and uses thereof
US12492224B2 (en) * 2018-12-21 2025-12-09 Bicycletx Limited Bicyclic peptide ligands specific for PD-L1
GB201912320D0 (en) * 2019-08-28 2019-10-09 Bicycletx Ltd PBP Binding Bicyclic Peptide Ligands
KR20230107589A (ko) 2020-11-13 2023-07-17 바이사이클티엑스 리미티드 트랜스페린 수용체 1 (TfR1)에 특이적인 비시클릭 펩티드 리간드

Also Published As

Publication number Publication date
WO2022101633A1 (en) 2022-05-19
AU2021376917A1 (en) 2023-06-29
IL302713A (en) 2023-07-01
JP2023549229A (ja) 2023-11-22
EP4244235A1 (en) 2023-09-20
US20250340595A1 (en) 2025-11-06
JP7848202B2 (ja) 2026-04-20
MX2023005624A (es) 2023-05-24
US20220194988A1 (en) 2022-06-23
AU2021376917A9 (en) 2024-09-12
AR126029A1 (es) 2023-09-06
CN116802190A (zh) 2023-09-22
SA523440745B1 (ar) 2024-07-24
US20240391959A1 (en) 2024-11-28
US11970555B2 (en) 2024-04-30
CA3201414A1 (en) 2022-05-19
TW202233664A (zh) 2022-09-01

Similar Documents

Publication Publication Date Title
US11970555B2 (en) Bicyclic peptide ligands specific for transferrin receptor 1 (TfR1)
CN1823088B (zh) 结合红细胞生成素受体的新肽
CA2833515C (en) High-affinity, dimeric inhibitors of psd-95 as efficient neuroprotectants against ischemic brain damage and for treatment of pain
US20080269114A1 (en) Y4 Selective Receptor Agonists For Thereapeutic Interventions
CA2559838A1 (en) Y2 selective receptor agonists for therapeutic interventions
WO2005089229A2 (en) Vpac1 selective antagonists and their pharmacological methods of use
CN100425282C (zh) 用于治疗性干预的y2/y4选择性受体激动剂
MXPA06010346A (es) Agonistas de receptor selectivo de y2/y4 para intervenciones terapeuticas.
TWI921406B (zh) 特用於運鐵蛋白受體之雙環胜肽配體、包含該配體的多聚體結合複合物、藥物組合物、組織輸送複合物及其用途
US20250276073A1 (en) BICYCLIC PEPTIDE LIGANDS SPECIFIC FOR TRANSFERRIN RECEPTOR 1 (TfR1)
EA049362B1 (ru) БИЦИКЛИЧЕСКИЕ ПЕПТИДНЫЕ ЛИГАНДЫ, СПЕЦИФИЧЕСКИЕ ДЛЯ РЕЦЕПТОРА ТРАНСФЕРРИНА 1 (TfR1)
WO2025099047A1 (en) BICYCLIC PEPTIDE LIGANDS SPECIFIC FOR TRANSFERRIN RECEPTOR 1 (TfR1)
Kutina et al. Synthesis of new vasotocin analogues: effects on renal water and ion excretion in rats
CN117120459A (zh) 抗感染双环肽配体
CA2425804A1 (en) Urotensin-ii agonists and antagonists
US11904020B2 (en) Bicyclic peptide ligands specific for TREM2
KR20160126519A (ko) 발기부전 치료 활성을 가지는 펩티드 및 이를 포함하는 조성물
CN117337295A (zh) 特异于trem2的双环肽配体
JP2001302695A (ja) Ｇｌｎ結合型糖鎖付加カルシトニン誘導体
CA2178927A1 (en) Peptide inhibitors of cxc intercrine molecules
HK1106138A (en) Y4 selective receptor agonists for therapeutic interventions
JP2001199998A (ja) カルシトニン３，２６位誘導体

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20230519

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20241106

Comment text: Request for Examination of Application